n-3 polyunsaturated fatty acids and mechanisms to mitigate inflammatory paracrine signaling in obesity-associated breast cancer.

Abstract

Globally, the prevalence of obesity is increasing which subsequently increases the risk of the development of obesity-related chronic diseases. Low-grade chronic inflammation and dysregulated adipose tissue inflammatory mediator/adipokine secretion are well-established in obesity, and these factors increase the risk of developing inflammation-associated cancer. Breast cancer is of particular interest given that increased inflammation within the subcutaneous mammary adipose tissue depot can alter the local tissue inflammatory microenvironment such that it resembles that of obese visceral adipose tissue. Therefore, in obese women with breast cancer, increased inflammatory mediators both locally and systemically can perpetuate inflammation-associated pro-carcinogenic signaling pathways, thereby increasing disease severity. Herein, we discuss some of these inflammation-associated pro-carcinogenic mechanisms of the combined obese breast cancer phenotype and offer evidence that dietary long chain n-3 polyunsaturated fatty acids (PUFA) may have utility in mitigating the severity of obesity-associated inflammation and breast cancer.

• Authors: Jennifer M Monk, Harmony F Turk, Danyelle M Liddle, Anna A De Boer, Krista A Power, David W L Ma, Lindsay E Robinson
• Journal: Nutrients (Nutrients) Vol. 6 Issue 11 Pg. 4760-93 (Oct 30 2014) ISSN: 2072-6643 [Electronic] Switzerland
• PMID: 25360510 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Adiponectin
• Cytokines
• Estrogens
• Fatty Acids, Omega-3
• Fatty Acids, Omega-6
• Leptin
• Aromatase

Topics

• Adiponectin (metabolism)
• Aromatase (metabolism)
• Breast Neoplasms (complications, drug therapy, epidemiology)
• Cytokines (metabolism)
• Estrogens (metabolism)
• Fatty Acids, Omega-3 (administration & dosage)
• Fatty Acids, Omega-6 (administration & dosage)
• Female
• Humans
• Inflammation (complications, drug therapy)
• Intra-Abdominal Fat (drug effects, metabolism)
• Leptin (metabolism)
• Obesity (complications, drug therapy, epidemiology)
• Paracrine Communication (drug effects)
• Prevalence